{"id":16668,"date":"2021-03-05T10:04:06","date_gmt":"2021-03-05T01:04:06","guid":{"rendered":"https:\/\/plaza.umin.ac.jp\/sawamura\/?p=16668"},"modified":"2021-09-04T13:09:57","modified_gmt":"2021-09-04T04:09:57","slug":"pediatricdiffusehighgrageglioma","status":"publish","type":"post","link":"https:\/\/plaza.umin.ac.jp\/sawamura\/glioma\/pediatricdiffusehighgrageglioma\/","title":{"rendered":"\u5c0f\u5150\u30bf\u30a4\u30d7\u306e\u3073\u307e\u3093\u6027\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de Pediatric-type diffuse high-grade gliomas"},"content":{"rendered":"

\u5c0f\u5150\u30bf\u30a4\u30d7\u306e\u3073\u307e\u3093\u6027\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u30002021\u5e74\u306eWHO\u5206\u985e\u306f4\u7a2e\u985e<\/h3>\n

\u81a0\u82bd\u816b glioblastoma\u3068\u3044\u3046\u8a3a\u65ad\u540d\u3092\u5c0f\u5150\u306e\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u306f\u4f7f\u7528\u3057\u306a\u3044\u3068\u3044\u3046\u539f\u5247\u306e\u305f\u3081\u306b\u8a2d\u3051\u3089\u308c\u305f\u5206\u985e\u3067\u3059<\/h3>\n

\u3073\u307e\u3093\u6027\u6b63\u4e2d\u30b0\u30ea\u30aa\u30fc\u30de\u00a0 H3 K27\u907a\u4f1d\u5b50\u7570\u5e38<\/strong>\u00a0(\u30b0\u30ec\u30fc\u30c94)<\/span><\/a>
\nDiffuse midline glioma<\/strong>, H3 K27-altered<\/strong><\/span><\/h5>\n
    \n
  • \u3053\u308c\u306f\u5225\u30da\u30fc\u30b8\u306b\u304f\u308f\u3057\u304f\u8a18\u8f09\u3057\u3066\u3044\u307e\u3059\u4e0a\u3092\u30af\u30ea\u30c3\u30af\u3057\u3066\u304f\u3060\u3055\u3044<\/li>\n
  • \u3073\u307e\u3093\u6027\u6a4b\u81a0\u816b\uff0cDIPG\uff0c\u8133\u5e79\u90e8\u795e\u7d4c\u81a0\u816b\u3068\u547c\u3070\u308c\u308b\u3082\u306e\u3067\u3059<\/li>\n
  • \u5c0f\u5150\u306e\u3073\u307e\u3093\u6027\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u3067\u306f\u3082\u3063\u3068\u3082\u591a\u3044\u3082\u306e\u3067\u3059<\/li>\n<\/ul>\n
    \u3073\u307e\u3093\u6027\u5c0f\u5150\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u00a0(\u30b0\u30ec\u30fc\u30c94)<\/strong>
    \nDiffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype<\/strong><\/h5>\n
      \n
    • IDH\u306b\u3082histone 3\u306b\u3082\u5909\u7570\u306e\u306a\u3044\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u3067\u3059<\/li>\n
    • \u4e88\u5f8c\u306f\u81a0\u82bd\u816b\u306b\u985e\u4f3c\u3057\u307e\u3059<\/li>\n<\/ul>\n
      \u4e73\u5150\u534a\u7403\u6027\u30b0\u30ea\u30aa\u30fc\u30de<\/strong>
      \nInfant-type hemispheric glioma<\/strong><\/h5>\n
        \n
      • \u4e73\u5150\u306e\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u306f\uff0c\u7d44\u7e54\u50cf\u3067\u4f4e\u60aa\u6027\u5ea6\u306e\u3082\u306e\u306e\u4e88\u5f8c\u304c\u60aa\u304f\uff0c\u9ad8\u60aa\u6027\u5ea6\u306e\u3082\u306e\u306e\u4e88\u5f8c\u304c\u826f\u3044\u3053\u3068\u304c\u77e5\u3089\u308c\u3066\u3044\u307e\u3057\u305f<\/li>\n
      • MAPK pathway\u5909\u7570\u306e\u306a\u3044\u3082\u306e\u3067\uff0c\u4e88\u5f8c\u304c\u60aa\u3044\u30b0\u30ea\u30aa\u30fc\u30de\u306e\u4e00\u7fa4\u3092\u793a\u3059\u5206\u985e\u3067\u3059<\/li>\n
      • ALK, NTRK1\/2\/3, ROS1<\/i>, or MET<\/i> gene fusions\u304c\u8a8d\u3081\u3089\u308c\u307e\u3059<\/li>\n
      • Kinase fusion-positive\u306a\u816b\u760d\u306e\u4e88\u5f8c\u306f\u826f\u3044\u3068\u3055\u308c\u307e\u3059<\/li>\n<\/ul>\n

        Clarke M: Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discov 2020<\/p>\n

        <\/div>\n
        \u3073\u307e\u3093\u6027\u534a\u7403\u6027\u30b0\u30ea\u30aa\u30fc\u30de\u00a0H3.3 G34\u5909\u7570\u578b<\/strong>(\u30b0\u30ec\u30fc\u30c94)
        \nH3.3 G34-mutant diffuse hemispheric glioma (WHO grade 4)<\/h5>\n
          \n
        • MRI\u3067\u4e00\u898b\uff0c\u3073\u307e\u3093\u6027\u661f\u7d30\u80de\u816b\u30b0\u30ec\u30fc\u30c92\u306e\u3088\u3046\u306b\u307f\u3048\uff0c\u5b9f\u306f\u9ad8\u60aa\u6027\u5ea6\u816b\u760d\u3067\u3042\u308b\u3082\u306e\u3067\u3059<\/li>\n
        • \u601d\u6625\u671f\u304b\u3089\u82e5\u3044\u6210\u4eba\u306e\u5927\u8133\u534a\u7403\u306b\u767a\u751f\u3059\u308b\u60aa\u6027\u816b\u760d\u3067\u3059<\/li>\n
        • \u5927\u8133\u306b\u5e83\u304f\u6d78\u6f64\u3057\u5927\u304d\u306a\u816b\u760d\u3068\u3057\u3066\u767a\u898b\u3055\u308c\u307e\u3059<\/li>\n
        • T2\/FLAIR\u3067\u3073\u307e\u3093\u6027\u306e\u9ad8\u4fe1\u53f7\u3092\u5448\u3057\u307e\u3059<\/li>\n
        • \u3057\u304b\u3057\uff0c\u62e1\u6563\u5f37\u8abf\u753b\u50cf DWI\u3067\u9ad8\u4fe1\u53f7<\/strong><\/span>\u3068\u306a\u308a\u307e\u3059<\/li>\n
        • \u3054\u304f\u4e00\u90e8\u304c\u30ac\u30c9\u30ea\u30cb\u30a6\u30e0\u5897\u5f37\u3055\u308c\u308b\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n
        • \u77f3\u7070\u5316\u3092\u4f34\u3046\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n
        • \u7d44\u7e54\u50cf\u3067\u306f\uff0c\u7d30\u80de\u7570\u578b\u6027\u304c\u9ad8\u304f\u81a0\u82bd\u816b\u3068\u985e\u4f3c\u306e\u3082\u306e\u3068\uff0cPNET\u306b\u4f3c\u305f\u80ce\u5150\u6027\u7d44\u7e54\u50cf\u3092\u793a\u3059\u3082\u306e\u304c\u3042\u308a\u307e\u3059<\/li>\n
        • \u81a0\u82bd\u816b\u3068\u306f\u7570\u306a\u308a\u8840\u7ba1\u5185\u76ae\u306e\u5897\u751f\u3084\u58ca\u6b7b\u304c\u898b\u3089\u308c\u306a\u3044\u3053\u3068\u304c\u3042\u308a\u307e\u3059<\/li>\n
        • \u75c5\u7406\u78ba\u5b9a\u306b\u306f\uff0cH3.3 G34 mutant,\u00a0IDH wildtype, nuclear ATRX lost\u3092\u8a3c\u660e\u3057\u307e\u3059<\/li>\n
        • MGMT promotor methylation\u304c\u3042\u308a\u307e\u3059<\/li>\n
        • \u81a0\u82bd\u816b\u3068\u540c\u3058\u6cbb\u7642\u304c\u306a\u3055\u308c\u307e\u3059<\/li>\n
        • \u751f\u5b58\u671f\u9593\u4e2d\u592e\u5024\u306f12-24\u30f6\u6708\u307b\u3069\u3067\u3059<\/li>\n<\/ul>\n

          Sturm D: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012<\/p>\n","protected":false},"excerpt":{"rendered":"

          \u5c0f\u5150\u30bf\u30a4\u30d7\u306e\u3073\u307e\u3093\u6027\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u30002021\u5e74\u306eWHO\u5206\u985e\u306f4\u7a2e\u985e \u81a0\u82bd\u816b glioblastoma\u3068\u3044\u3046\u8a3a\u65ad\u540d\u3092\u5c0f\u5150\u306e\u9ad8\u60aa\u6027\u5ea6\u30b0\u30ea\u30aa\u30fc\u30de\u306b\u306f\u4f7f\u7528\u3057\u306a\u3044\u3068\u3044\u3046\u539f\u5247\u306e\u305f\u3081\u306b\u8a2d\u3051\u3089\u308c\u305f\u5206\u985e\u3067\u3059 \u3073\u307e\u3093\u6027\u6b63\u4e2d\u30b0\u30ea\u30aa\u30fc\u30de\u00a0 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-16668","post","type-post","status-publish","format-standard","hentry","category-glioma"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/16668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/comments?post=16668"}],"version-history":[{"count":7,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/16668\/revisions"}],"predecessor-version":[{"id":18174,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/posts\/16668\/revisions\/18174"}],"wp:attachment":[{"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/media?parent=16668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/categories?post=16668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/plaza.umin.ac.jp\/sawamura\/wp-json\/wp\/v2\/tags?post=16668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}